Publications by authors named "Christopher J Stotka"
GW320659 for the treatment of attention-deficit/hyperactivity disorder in children.
Joseph DeVeaugh-Geiss C Keith Conners Elias H Sarkis Paul K Winner Lawrence D Ginsberg Christopher J Stotka
J Am Acad Child Adolesc Psychiatry
August 2002
Objective: To assess the safety, tolerability, and efficacy of GW320659, a chemically novel inhibitor of norepinephrine and dopamine reuptake, in pediatric attention-deficit/hyperactivity disorder (ADHD).
Method: This was a multicenter, open-label, dose-titration study of seven daily dose levels of GW320659: 1.25, 2.